OUTLOOK THERAPEUTICS INC (OTLK) - Total Liabilities
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has total liabilities worth $50.77 Trillion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore OTLK long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
OUTLOOK THERAPEUTICS INC - Total Liabilities Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OTLK total asset value.
OUTLOOK THERAPEUTICS INC Competitors by Total Liabilities
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Glacier Media Inc.
TO:GVC
|
Canada | CA$84.79 Million |
|
Industrial Investment Trust Limited
NSE:IITL
|
India | Rs41.88 Million |
|
Bumyang Construction Co Ltd
KO:002410
|
Korea | ₩183.17 Billion |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
USA | $74.47 Million |
|
Guler Yatirim Holding AS
IS:GLRYH
|
Turkey | TL10.53 Billion |
|
NBI Bearings Europe S.A.
MC:NBI
|
Spain | €78.46 Million |
|
Monalisa
KO:012690
|
Korea | ₩15.67 Billion |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
Korea | ₩160.29 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down OUTLOOK THERAPEUTICS INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OUTLOOK THERAPEUTICS INC balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1577369.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OUTLOOK THERAPEUTICS INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $50.77 Trillion | +49825230.14% |
| 2024-09-30 | $101.90 Million | +118.02% |
| 2023-09-30 | $46.74 Million | +136.16% |
| 2022-09-30 | $19.79 Million | +8.72% |
| 2021-09-30 | $18.20 Million | +7.67% |
| 2020-09-30 | $16.91 Million | -39.41% |
| 2019-09-30 | $27.90 Million | -35.25% |
| 2018-09-30 | $43.09 Million | -16.26% |
| 2017-09-30 | $51.46 Million | +78.03% |
| 2016-09-30 | $28.91 Million | -17.77% |
| 2015-09-30 | $35.15 Million | -45.30% |
| 2014-09-30 | $64.26 Million | -- |
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more